toradol

Not all of the dangerous, controversial drugs are banned in baseball

64 Comments

We get up in arms about testosterone and HGH — substances our bodies naturally produce and which have few serious side effects or long-lasting consequences — because they’re on a banned list. Meanwhile there’s a drug that a lot of athletes take under the direction and supervision of their teams which can kill people and is banned in several countries: the anti-inflammatory Toradol.

Gordon Edes of ESPN Boston has a story about its use in baseball. The hook: an interview with Jonathan Papelbon who took it routinely when he was with the Red Sox but who was told by the Phillies that he can no longer take it as they do not allow it.  Edes looks into the controversial drug, notes its serious side effects, which can include internal bleeding (Clay Buchholz believes it’s what led to him contracting esophagitis which landed him in the ICU) and notes that it’s banned in several countries, for athletes and normal folks alike.

Papelbon’s description of its use in Major League Baseball is pretty familiar-sounding: it’s taken before the game to help guys “get through a 162 game season.” It’s, by definition, a performance enhancing drug. It’s letting guys do things they otherwise couldn’t do. Allowing their bodies to recover faster which allows them to train harder and compete at a more intense level than they otherwise could. Except it’s not on a banned list so no one cares despite the fact that it has the potential to kill you.

There is a tremendous disconnect between the drugs people think are awful in sports and the drugs that truly have the potential to be harmful. This is maybe the best example. Might be nice if we thought about our priorities about these things once in a while.

Braves sign reliever Carlos Torres

Screenshot 2016-02-10 at 7.00.22 PM
Rich Schultz/Getty Images North America
Leave a comment

As first reported by Bill Shanks of Fox Sports 1670, the Braves have signed right-handed reliever Carlos Torres to a minor league contract with an invitation to spring training.

Torres was waived by the Mets in January, somewhat surprisingly, and elected to become a free agent. The 33-year-old ultimately chose Atlanta, where he should have a good shot at an Opening Day roster out of spring training with the rapidly-rebuilding Braves.

Torres posted an ugly 4.68 ERA in 57 2/3 innings last season for the Mets, but he registered a gorgeous 3.06 ERA and 96 strikeouts across 97 innings in 2014.

If he gets off to a good start in 2016, he could become valuable trade bait.

Blue Jays will have a closer competition this spring

Screenshot 2016-02-10 at 6.22.24 PM
Tom Szczerbowski/Getty Images North America
Leave a comment

Roberto Osuna became the youngest pitcher to ever play for the Blue Jays last season at age 20 and he rose to the challenge with a 2.58 ERA, 0.92 WHIP, and 75/16 K/BB ratio in 69 2/3 frames. Osuna eventually took over as Toronto’s closer, earning 20 regular-season saves and one in the American League Division Series — a five-out effort in Game 5 to close out the visiting Rangers.

But the Jays upgraded the back end of their bullpen this winter, acquiring Drew Storen from the Nationals in early January for speedy outfielder Ben Revere. Jesse Chavez was also brought to Toronto in a trade with the A’s.

Storen has more experience at closer than Osuna, and Storen struggled when the Nationals tried to put him in a setup role. Storen, in his final year of salary arbitration, also gets paid much more. He’s probably going to enter spring training as the favorite for the Jays’ ninth-inning gig, but there will be a competition …

Blue Jays general manager Ross Atkins told Ben Nicholson-Smith of Sportsnet.ca on Wednesday that he doesn’t expect the team to choose between Osuna or Storen until midway through spring training, if not later.

There’s been talk of making Osuna a starter, so add that wrinkle.

Storen, 28, boasts 95 career major league saves.

Orioles plotting late-offseason push? Gallardo, Fowler, Alvarez, Bruce in consideration

orioles logo
2 Comments

Baltimore’s front office appears to be lining up a run of potential roster additions leading into the beginning of spring training.

We’ve already passed along the reports suggesting they are close to a three-year deal with free agent starter Yovani Gallardo, but now FOX Sports’ Ken Rosenthal adds that free agent outfielder Dexter Fowler could be next on the Orioles’ target list. It they get those two deals done, the O’s could then chase free agent slugger Pedro Alvarez.

Rosenthal says the Orioles are even eyeing Jay Bruce of the Reds, though the FOX reporter hears the O’s might not have the prospects to pull off that kind of trade.

The focus for the Orioles out of the gate this winter was re-signing Matt Wieters and Chris Davis. Wieters accepted his one-year, $15.8 million qualifying offer in November and Davis was locked up to a seven-year, $161 million contract in mid-January.

Now the O’s are spending a little leftover cash on late-offseason additions to improve their position in what should be a tight 2016 American League East race.

Brandon Belt signs $6.2 million deal, avoiding arbitration with Giants

Brandon Belt
1 Comment

In a last-second compromise before a scheduled heading today, first baseman Brandon Belt and the Giants have avoided arbitration by agreeing to a one-year, $6.2 million deal.

Belt requested $7.5 million and the Giants countered at $5.3 million, so they’ve settled slightly on the team-friendly side of the midpoint. Belt will be arbitration eligible again next season for the final time before hitting the open market as a free agent.

He’s coming off a very good season in which he hit .280 with 18 homers and an .834 OPS in 137 games and Belt has a lifetime .803 OPS through age 27, making him one of MLB’s most underrated all-around first baseman.